Braveheart Bio, Inc.
Research Braveheart Bio, Inc. (BRVE) on Bullrun: market cap USD 1.67B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBRVE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.67B
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 14.99M
- Free cash flow-USD 16.94M
Valuation Snapshot
latest market cap is USD 1.67B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 66.05M | -USD 35.58M | n/a | -5.32 | USD 89.16M | n/a | -USD 65.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 1.67B | n/a | n/a | n/a |
About Braveheart Bio, Inc.
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Braveheart Bio, Inc.'s market cap?
Braveheart Bio, Inc.'s market capitalization is USD 1.67B.
What does Braveheart Bio, Inc. do?
Braveheart Bio, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. It develops and offers BHB-1893 and HRS-1893, an oral small-molecule cardiac myosin inhibitor (CMI) for the treatment of obstructive HCM and non-obstructive HCM. The company was incorporated in 2024 and is headquartered in San Francisco, California.